AbCellera Biologics Inc
ABCL
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.2B
Close$
$-3.70
126.9% downside
Current Fair Value
126.9% downsideOvervalued by 126.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.20 Billion |
|---|---|
| Enterprise Value | $4.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.49 |
| Beta | 1.19 |
| Outstanding Shares | 305,557,294 |
Return
| Return on Equity | -18.38% |
|---|---|
| Return on Assets | -12.59% |
| Return on Invested Capital | -16.32% |
Valuation & Multiples
| P/E Ratio | -25.44 |
|---|---|
| PEG | -42.69 |
| Price to Sales | - |
| Price to Book Ratio | 6.87 |
| Enterprise Value to Revenue | 63.95 |
| Enterprise Value to EBIT | -20.67 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$7.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$6.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5870▼ 151.11% |
|---|---|
| Total Calls | 4,068,200▲ 146.20% |
| Total Puts | 2,387,900▼ 31.12% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 38.00%▼ 3.01% |
|---|---|
| Total Invested | $908.86M▲ 109.43% |
| Investors Holding | 167▲ 15.00% |
ESG Score
No data